Novo Nordisk (NVO)
(Delayed Data from NYSE)
$132.06 USD
+0.06 (0.05%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $132.30 +0.24 (0.18%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
NVO 132.06 +0.06(0.05%)
Will NVO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVO
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
Tap the Weight-Loss Drug Market With These ETFs
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
Novo Nordisk (NVO) Outperforms Broader Market: What You Need to Know
Other News for NVO
Hims & Hers compounded weight loss med $99/month for military, first responders
Sen. Sanders says generic drugmakers willing to sell Ozempic for less than $100
Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
PRESS: Novo Nordisk executive warns Ozempic a target for US price cap
BlackRock Multi-Asset Income Fund Q2 2024 Commentary